A new gene therapy called Zynteglo could eliminate iron-rich blood transfusions used to treat patients with beta thalassemia that causes severe anemia but it costs around $2.8 million. NBC News’ Anne ...
The development and approval of gene therapies has been a potential game changer for patients with beta-thalassaemia who have been dependent on regular red blood cell transfusions -- a substantial ...
Lentiviral vector (LV)–based gene therapy using CD34+ hematopoietic stem cells (HSCs) demonstrated stable factor VIII expression in severe hemophilia A patients, with higher vector copy numbers ...
Verve Therapeutics (VERV) is revolutionizing the approach to cardiovascular disease treatment through pioneering gene-editing therapies that provide lifelong cholesterol control after a single ...
RegenXBio Inc. (RGNX) announced an update on their ongoing clinical study. RegenXBio Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, Open-Label Study to Evaluate the Efficacy, Safety, ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Ocugen Inc. is currently conducting a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback